Alpha-Lipoic Acid Supplementation and IVF Outcomes in Women of Advanced Maternal Age
Effects of Alpha-Lipoic Acid Supplementation on Oocyte Quality, Cumulus Cell Mitochondrial Function, and In Vitro Fertilization Outcomes in Infertile Women of Advanced Maternal Age: A Prospective Cohort Study
Kaohsiung Veterans General Hospital.
60 participants
Jun 11, 2026
INTERVENTIONAL
Conditions
Summary
Female fertility declines with advancing age, largely because of deteriorating oocyte quality driven by mitochondrial dysfunction and oxidative stress within the ovarian microenvironment. Alpha-lipoic acid (ALA) is a potent antioxidant that crosses cell and mitochondrial membranes, regenerates other antioxidants (vitamin C, vitamin E, glutathione, coenzyme Q10), and supports mitochondrial respiratory chain activity and ATP production. This prospective study will enroll 60 infertile women aged 35-45 years undergoing in vitro fertilization (IVF) treatment. Thirty participants will receive oral ALA 600 mg/day for two months before their IVF cycle, and thirty will proceed directly to IVF without supplementation. The study will compare oocyte and embryo quality, cumulus cell mitochondrial function and metabolic gene expression, and clinical pregnancy and live birth rates between the two groups.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral Alpha-Lipoic Acid 600 mg/day for 2 months prior to IVF cycle initiation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07685431